Condition: Polycythemia Vera (PV) · Myelofibrosis (MF) · Myeloproliferative Neoplasms (MPNs) · Sponsor: Prelude Therapeutics
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\[s\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
This description comes directly from the study's public registry record.
Study Contact (Please Do Not Disclose Personal Information) · See Email · clinicaltrials@preludetx.com
Always discuss trial participation with your own doctor first.
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| BRCR Global - Coral Springs | Coral Springs, Florida, United States | Recruiting |
| START Midwest, LLC | Grand Rapids, Michigan, United States | Recruiting |
| Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office | Philadelphia, Pennsylvania, United States | Recruiting |
| Tristar BMT | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07469891